Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Bassan R, et al. Among authors: di bona e. Blood. 2009 Apr 30;113(18):4153-62. doi: 10.1182/blood-2008-11-185132. Epub 2009 Jan 13. Blood. 2009. PMID: 19141862 Free article.
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.
Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, Vannucchi AM, Mappa S, Rossi G, Rossi V, Di Bona E, Paratore S, Carobbio A, Rambaldi A, Barbui T, Bassan R. Intermesoli T, et al. Among authors: di bona e. Br J Haematol. 2009 Dec;147(5):681-5. doi: 10.1111/j.1365-2141.2009.07893.x. Epub 2009 Sep 4. Br J Haematol. 2009. PMID: 19735261 Free article. Clinical Trial.
Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani EM, Di Bona E, Cassibba V, Scattolin AM, Romani C, Ciceri F, Cortelezzi A, Gianfaldoni G, Mattei D, Audisio E, Rambaldi A. Bassan R, et al. Among authors: di bona e. Blood Cancer J. 2014 Jul 11;4(7):e225. doi: 10.1038/bcj.2014.48. Blood Cancer J. 2014. PMID: 25014772 Free PMC article. No abstract available.
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A. Barcellini W, et al. Among authors: di bona e. Blood. 2014 Nov 6;124(19):2930-6. doi: 10.1182/blood-2014-06-583021. Epub 2014 Sep 16. Blood. 2014. PMID: 25232059 Free article.
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Castagnetti F, et al. Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19. Leukemia. 2015. PMID: 26088952 Clinical Trial.
Low-dose rituximab in autoimmune hemolytic anemia: 10 years after.
Fattizzo B, Zaninoni A, Pettine L, Cavallaro F, Di Bona E, Barcellini W. Fattizzo B, et al. Among authors: di bona e. Blood. 2019 Feb 28;133(9):996-998. doi: 10.1182/blood-2018-12-885228. Epub 2019 Jan 22. Blood. 2019. PMID: 30670440 Free article. No abstract available.
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F. Cicconi L, et al. Among authors: di bona e, di renzo n. Leukemia. 2020 Mar;34(3):914-918. doi: 10.1038/s41375-019-0589-3. Epub 2019 Oct 14. Leukemia. 2020. PMID: 31611624 Clinical Trial. No abstract available.
COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.
Barcellini W, Fattizzo B, Giannotta JA, Quattrocchi L, Aydin S, Barone F, Carbone C, Pomponi F, Metafuni E, Beggiato E, Sica S, Di Bona E, Lanza F, Notaro R, Iori AP. Barcellini W, et al. Among authors: di bona e. Br J Haematol. 2021 Sep;194(5):854-856. doi: 10.1111/bjh.17558. Epub 2021 May 25. Br J Haematol. 2021. PMID: 34036575 Free PMC article. No abstract available.
93 results